Anti-Human EGFR (Clone EGFR.1) – Purified in vivo PLATINUM™ Functional Grade

Use of Clone EGFR.1 in In Vivo Mouse Studies

There is no direct evidence in the provided search results for a clone named "EGFR.1" being used in in vivo mouse studies. However, the results discuss related topics and antibodies that may clarify the scientific context.

Evidence from Search Results

• No Direct Mention of EGFR.1: None of the cited studies or product listings reference a clone called "EGFR.1" for in vivo use in mice.
• Related Antibodies: The studies discuss other anti-EGFR antibodies, such as 7A7, which was explored as a potential "mouse cetuximab" for preclinical studies. However, 7A7 was found not to recognize mouse EGFR effectively in vivo and did not impact tumor regression or survival in tested models, indicating that not all anti-EGFR clones are suitable for mouse studies.
• EGFR-Targeted Studies in Mice: Other in vivo approaches include using EGFR-specific peptides for imaging and generating genetically engineered mouse models (GEMMs) with EGFR mutations to study lung adenocarcinoma and response to tyrosine kinase inhibitors. These models rely on genetic modification of the mouse Egfr gene rather than antibody-based targeting.

Typical Use of Anti-EGFR Clones in Mice

While "EGFR.1" is not specifically documented here, in general, anti-EGFR monoclonal antibodies (clones) are used in mouse studies to:

• Block EGFR Signaling: By binding to the extracellular domain of EGFR, these antibodies can inhibit ligand binding and downstream signaling, mimicking therapeutic strategies used in humans (e.g., cetuximab).
• Study Tumor Biology: Antibodies can be used to assess the role of EGFR in tumor growth, metastasis, and response to therapy.
• Imaging: EGFR-targeted agents (antibodies or peptides) can be conjugated to imaging probes to visualize EGFR-expressing tumors in vivo.
• Evaluate Immune Mechanisms: Some studies aim to dissect the contribution of immune effector mechanisms (e.g., ADCC) to anti-EGFR therapy.

Key Considerations

• Species Specificity: Not all anti-EGFR antibodies cross-react between species. For example, 7A7 does not function as an effective anti-mouse EGFR antibody in vivo, despite initial claims.
• Model Systems: Researchers often use human tumor xenografts in immunodeficient mice or genetically engineered mice with altered Egfr to study EGFR biology and therapy.
• Validation: Any new clone (including hypothetical "EGFR.1") would require rigorous validation for specificity, affinity, and functional activity in mouse systems before use in vivo.

Conclusion

There is no evidence in the provided results that a clone named "EGFR.1" has been used in in vivo mouse studies. For such studies, researchers typically use either species-specific anti-EGFR antibodies (with demonstrated activity in mice), genetically engineered mouse models, or human xenografts in immunodeficient mice. Any new clone intended for in vivo use would need extensive preclinical validation to ensure it effectively targets mouse EGFR and elicits the desired biological effects. If you have a specific reference or context for "EGFR.1," more targeted information may be required.

The correct storage temperature for the sterile packaged clone EGFR.1 depends on its formulation and labeling by the manufacturer, but for the commonly available anti-EGFR monoclonal antibody (Clone: EGFR.1), the recommended storage temperature is 2–8°C (refrigerated), protected from light, and it should not be frozen.

Some additional context:

• Products such as "Anti-EGFR Monoclonal Antibody (Clone:EGFR1)-PE Conjugated" specify storage at 2–8°C in the dark and explicitly caution not to freeze.
• Other similar antibodies, if shipped lyophilized, may recommend storage at -20°C. However, for liquid or ready-to-use conjugated versions, 2–8°C and protection from light are standard.

Always defer to the supplier’s product datasheet for your specific batch to ensure correct storage. Most commercial EGFR.1 antibody datasheets (including conjugated forms) recommend storage at 2–8°C and specify not to freeze.

Commonly used antibodies or proteins studied alongside EGFR (Epidermal Growth Factor Receptor)—including when "EGFR.1" is referenced as a clone or reagent—often include other EGFR family members, EGFR-targeted drugs, and signaling pathway markers.

Key proteins and antibodies frequently used in combination with EGFR antibodies in the literature include:

• Other EGFR family receptors:
  • HER2/ErbB2, HER3/ErbB3, HER4/ErbB4 (these are structurally related and often co-expressed or co-studied with EGFR, especially in cancer research).
• Common anti-EGFR monoclonal antibodies (mAbs):
  • Cetuximab (C225/225 clone), Panitumumab, Matuzumab, Necitumumab, Nimotuzumab, Futuximab (Sym004), Duligotuzumab, Depatuxizumab, Zalutumumab, GC1118, and Imgatuzumab.
• EGFR tyrosine kinase inhibitors (TKIs):
  • Gefitinib and Erlotinib—used in combination with EGFR antibodies for functional studies, especially evaluating synergistic anti-tumor effects.
• Downstream signaling proteins and pathway markers:
  • Phospho-EGFR, AKT, Phospho-AKT, ERK1/2, Phospho-ERK, STAT3, and PI3K—these are common readouts to assess the functional impact of EGFR inhibition or activation in cells.
• Ligands and alternate surface receptors:
  • EGF (epidermal growth factor) and related ligands may be measured for receptor activity modulation.
  • Cross-linking experiments sometimes use combinations of mAbs targeting different EGFR epitopes for receptor downregulation potency (e.g., combinations of noncompetitive mAbs like 225/cetuximab and H11).

In cancer studies, EGFR is often used with markers for:

• Cell proliferation and apoptosis: Ki67, Cleaved Caspase-3
• Epithelial and mesenchymal markers: E-cadherin, Vimentin
• Other diagnostic markers specific to tumor type (e.g., cytokeratins in carcinomas)

Summary table of commonly used antibodies/proteins with EGFR:

Note:

• If your EGFR.1 reference is a specific antibody clone, it is commonly accompanied by antibodies against the above proteins for context or pathway analysis.
• Combination strategies are especially prominent in cancer cell line models, where mAbs and TKIs are used together to study additive or synergistic effects on EGFR signaling and cell viability.
• Additional context-specific markers may be used depending on tissue or tumor type.

For highly specific companion antibodies with clone "EGFR.1" (if referencing a distinct antibody clone), literature sometimes pairs it directly with other anti-EGFR mAbs (e.g., clone 225/cetuximab) to probe for non-overlapping epitopes or to maximize receptor downregulation.

Key findings from scientific literature citing clone EGFR.1 (a monoclonal antibody used against the Epidermal Growth Factor Receptor, EGFR) are centered on its applications in research and diagnostics, particularly in oncology. The literature on clone EGFR.1 itself is somewhat limited, but citations frequently discuss the following themes:

• Detection and Quantification of EGFR Expression: Clone EGFR.1 is commonly used in immunohistochemistry (IHC) and flow cytometry protocols for detecting EGFR in tumor samples. Its specificity for human EGFR allows researchers to distinguish EGFR-expressing tumor cells from non-expressing cells, underpinning both diagnostic and research applications.

• EGFR as a Predictive and Prognostic Marker: Studies using EGFR.1 contribute to the evidence that EGFR expression and gene copy number can serve as predictive biomarkers for the efficacy of anti-EGFR therapies, especially in cancers like colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). For example:

  • High EGFR gene copy number has been linked with better response rates to anti-EGFR monoclonal antibodies (e.g., cetuximab, panitumumab) in metastatic CRC.
  • However, discrepancies remain—some studies report no clear correlation between protein expression (measured with clones like EGFR.1) and clinical benefit, while gene copy number may be a stronger predictor.

• Role in Resistance and Treatment Strategies:

  • Recent translational studies have shown that acquired resistance mutations in EGFR (often detected with molecular tools guided by antibody-based profiling) undergo exponential decay after cessation of anti-EGFR therapy, influencing strategies for re-challenging patients with EGFR inhibitors. While these studies frequently use sequencing and liquid biopsy, initial tumor profiling—including with antibodies like EGFR.1—remains foundational in patient stratification.

• Technical and Validation Aspects:

  • Clone EGFR.1 is often compared to other anti-EGFR antibodies in terms of specificity, sensitivity, and background staining. Literature notes the necessity of antibody validation for accurate diagnostic results.
  • Some newer studies focus more on sequencing or multiplexed quantitative methods to assess EGFR status, but IHC with EGFR.1 remains a standard, validated technique in many clinical labs.

• Methodological Limitations and Consensus:

  • Research highlights the importance of standardized protocols for the use of EGFR.1 in pathology, as differences in tissue processing or scoring systems can affect the reproducibility of results.
  • There is ongoing debate about whether protein expression (measured with EGFR.1) or gene copy number (measured by molecular techniques) is more predictive of patient outcome, particularly with anti-EGFR therapies in NSCLC and CRC. Some consensus exists that gene copy number may have a stronger predictive value, but EGFR IHC (using clones such as EGFR.1) is still in widespread use.

In summary, clone EGFR.1 is an important reagent for identifying EGFR expression in human tumors, contributing to diagnostics, prognostication, and research into targeted therapies. While molecular methods increasingly supplement or supplant protein-based detection for certain clinical decisions, antibodies like EGFR.1 underpin much of the foundational work and ongoing routine analysis in cancer pathology.